Metabolic Research Stack — Incretin Pharmacology Reference
Reviewed by the BestHealingPeptides Editorial Team ·
Map the pharmacological space available for metabolic-disease and obesity research, distinguishing licensed incretin pharmacology (semaglutide, tirzepatide) from complementary research-only AMPK-pathway (MOTS-c, 5-Amino-1MQ) and lipolytic (AOD-9604) compounds. This page is a reference framework, NOT a recommendation for combined clinical use.
Components
Semaglutide
metabolic
Tirzepatide
metabolic
MOTS-c
metabolic · longevity
5-Amino-1MQ
metabolic
AOD-9604
regeneration · joint
Protocol notes
CRITICAL: Semaglutide and tirzepatide are MHRA-licensed prescription medicines (POMs) with established efficacy, safety, and regulatory pathways. They should be used clinically only under appropriate medical supervision and prescription. The other components (MOTS-c, 5-Amino-1MQ, AOD-9604) are pre-clinical research compounds without marketing authorisation. This 'stack' framing is for RESEARCH context only — characterising the mechanistic space and the pharmacological complementarity between incretin pathway and AMPK pathway compounds. Combined administration to humans of licensed incretin pharmacology with unlicensed research compounds is not supported by evidence, has not been evaluated for safety, and would engage Human Medicines Regulations 2012 with respect to the unlicensed components.
Mechanistic rationale — orthogonal metabolic pathways
The metabolic pharmacology space is organised around several pharmacologically distinct pathways. The incretin pathway (GLP-1R, GIPR, glucagon-R) drives appetite suppression, glucose-dependent insulin secretion, and slowed gastric emptying — the mechanism of the licensed semaglutide and tirzepatide products that has transformed type-2 diabetes and obesity therapeutics in the late 2020s. The AMPK pathway drives insulin-independent glucose disposal, fatty acid oxidation, and mitochondrial biogenesis — addressed pre-clinically by MOTS-c (mitochondrial-derived peptide) and (more broadly) by metformin and exercise. The NAD+/SAM pathway addresses cellular methyl-donor and NAD+ availability through NNMT inhibition (5-Amino-1MQ) and NAD+ precursor supplementation (NMN, NR). The lipolytic pathway addresses adipose-tissue lipid mobilisation directly through GH-axis activation (AOD-9604, the C-terminal GH fragment). These pathways are mechanistically orthogonal — they address different cellular targets without redundant pharmacology — and represent the conceptual scaffold of modern metabolic research. The mechanistic complementarity is the basis of legitimate combined research-protocol design in pre-clinical models, distinct from any combined clinical-use framework.
Component selection — incretin pharmacology choice
Among the incretin-pathway compounds, semaglutide is the longer-established and more extensively characterised choice with the deeper post-marketing safety dataset since 2017 licensure. Tirzepatide produces superior HbA1c and weight outcomes at maximum licensed doses based on head-to-head SURPASS-2 and SURMOUNT-5 data, but with shorter post-marketing surveillance. Retatrutide remains Phase III trial-only with the largest projected efficacy (24.2% mean weight loss at 12 mg in Phase II) but no current regulatory authorisation. For research where the incretin-pathway choice matters less than the broader mechanistic exploration, semaglutide is the conservative reference compound; for research targeting maximum incretin-pathway pharmacology, tirzepatide is the higher-efficacy choice. The receptor pharmacology (selective GLP-1R vs dual GLP-1R/GIPR) is the central mechanistic distinction; the head-to-head efficacy data establish tirzepatide superiority for empirical research purposes.
Endpoint suggestions
Pharmacodynamic endpoints for metabolic research: fasting glucose, HbA1c, fasting insulin and C-peptide for glucose homeostasis; OGTT or MMTT for incretin-effect characterisation; serum GLP-1, GIP, and glucagon for endogenous incretin axis monitoring. Body-composition endpoints: DEXA for lean and fat mass distribution; CT or MRI for visceral adipose tissue volume; bioelectrical impedance for clinic-friendly tracking. Lipid panel and apolipoproteins. Inflammatory markers: hsCRP, IL-6. Cardiovascular endpoints: blood pressure, heart rate; in chronic studies, echocardiographic LV function. Hepatic endpoints in NAFLD/MASH context: hepatic fat by MR spectroscopy, serum ALT/AST/GGT, ELF panel for fibrosis. Mechanistic readouts for AMPK pathway compounds: skeletal-muscle AMPK phosphorylation in research-context biopsies; mitochondrial biogenesis markers (PGC-1α, mtDNA copy number). The endpoint selection should match the specific pathway being researched rather than attempting to characterise all pathways simultaneously.
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.